Kura Oncology, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Kura Oncology, Inc. on June 20, 2018. The report discloses the appointment of a new Chief Operating Officer and the terms of his employment agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It is a current report focused on corporate governance and executive compensation rather than financial performance.
Material Changes
The primary material change is the appointment of John Farnam as Chief Operating Officer, effective July 1, 2018. Mr. Farnam brings 26 years of Marine Corps leadership experience and recent experience as Vice President of Business Operations at Celgene Receptos.
Management Commentary and Compensation Details
- Base Salary: $355,000 annually.
- Target Bonus: 40% of base salary.
- Termination Benefits: In the event of termination without "Cause" or resignation for "Good Reason," Mr. Farnam is entitled to a lump-sum payment equal to his annual base salary and up to 12 months of COBRA health insurance premiums.
- Change in Control: If termination occurs within 59 days before or 12 months after a Change in Control, benefits include the full target bonus for the year and accelerated vesting of 100% of outstanding unvested stock awards.
Investor Verification Checklist
- Verify the effective start date of the new COO (July 1, 2018).
- Review the specific definitions of "Cause" and "Good Reason" in the full Executive Employment Agreement.
- Confirm the current status of Mr. Farnam's stock awards and vesting schedules.
- Assess the impact of the new executive leadership on the company's clinical operations and strategic direction.